Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

Inclusion Criteria: * Has signed an informed consent form (ICF) before initiation of any study-specific procedures * Was \>18 years or age deemed to be an adult per local authorities inclusive, at the time of giving written informed consent * Were willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions, and other requirements of the study (per investigator assessment, must been capable of understanding and following study-related instructions) * Had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 * Had histologically or cytologically confirmed PDAC * Had macroscopically complete resection (R0 or R1 resection, Royal College of Pathologists \[RCP\] classification) performed between ≥21 and ≤84 days prior to Cycle 1, Day 1 (C1D1). Submission of formalin-fixed paraffin-embedded tissue (FFPE) tumor tissue from resection or biopsy was required * Had no radiologic (computed tomography/magnetic resonance imaging) evidence of metastatic disease, malignant ascites, or pleural effusion through an assessment obtained within 4 weeks of first study medication (i.e., C1D1) * Full recovery from surgery and able to receive chemotherapy * Had acceptable laboratory parameters * Was willing to allow collection of pharmacokinetic samples * Agreed not to enroll in another study of an IMP, starting after signing of the ICF and continuously until the last planned visit in this study * Participants of childbearing poten…